Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Chugai to Expand Range of Drugs on Its Medication Optimization Support Application
September 8, 2017
-
ACADEMIA AMED Study Group to Investigate Drugs to Recommend in Elderly Depression Patients; Findings to Be Reflected in New Guidelines
September 7, 2017
-
BUSINESS Spera Pharma Begins Business Capitalizing on “Takeda’s” Track Record, Aims to Become Japan’s No. 1 CDMO
September 6, 2017
-
ORGANIZATION JMA’s Imamura Questions Distribution Coefficient in Cost Calculation Formula
September 5, 2017
-
BUSINESS Mitsubishi Tanabe to Beef Up Marketing System in Field of Autoimmune Diseases, Plans to Expand Expert Sales Force
September 5, 2017
-
REGULATORY Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients
September 4, 2017
-
REGULATORY Programs Funded by MA Holder or Its Subsidiaries Subject to Regulations under Clinical Research Law
September 1, 2017
-
BUSINESS Daiichi Sankyo Denies Report on AZ’s Acquisition Offer
September 1, 2017
-
BUSINESS Daiichi Sankyo Share Trade Halted after Report on AZ’s Acquisition Offer
August 31, 2017
-
BUSINESS Fujifilm Holdings Aims to Achieve 500 Billion Yen in Healthcare Sales in FY2019
August 31, 2017
-
ACADEMIA Over 150 Clinical Trials of Epigenetic Drugs, Some with Novel Mechanisms of Action, Underway Worldwide
August 31, 2017
-
REGULATORY MHLW to Form Study Group to Address Leftover Vial Drug Issue, Weighs Multi-Dose Vials
August 30, 2017
-
BUSINESS Mitsubishi Tanabe to Create New Business by Fusing LLPs with Digital Technologies
August 30, 2017
-
REGULATORY New Minister Has Hopes for Pharma Industry in Both Medical and Economic Fronts, Wants to Balance Innovation and Cost
August 29, 2017
-
REGULATORY Opdivo’s Gastric Cancer Use, Avelumab and More Up for MHLW Panel Review/Report on Sept. 8
August 28, 2017
-
BUSINESS Spinraza to Hit Japan Market on August 30
August 28, 2017
-
REGULATORY MHLW Seeks 31.4 Trillion Yen in FY2018 Budget, 630 Billion Yen in Natural Rise for Social Security
August 25, 2017
-
REGULATORY Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
-
REGULATORY Spinraza’s 9.32 Million Yen Price Tag OK’ed for Listing on Aug. 30
August 23, 2017
-
BUSINESS External Activities of Takeda Unit Axcelead to Go Full Throttle This Autumn: President
August 23, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…